Findings {#Sec1}
========

Introduction {#Sec2}
------------

Leptin modulates hepatic insulin action \[[@CR1]\] and is a key regulator of carbohydrate homeostasis. Under physiological conditions, insulin modulates glucose fluxes by suppressing the expression of gluconeogenic genes and stimulating those associated with glucose uptake. Leptin is involved in these actions through stimulation of phosphatidylinositol-3 kinase \[[@CR2]\].

Intravenous \[[@CR3]\] and brain infusions of leptin \[[@CR4]\] alter hepatic glucose fluxes, improving glucose homeostasis. These effects on insulin's actions in peripheral organs have been examined in models of obesity and diabetes \[[@CR5]\], however; there is little information regarding the effects of an increase in central leptin bioavailability on hepatic insulin sensitivity in non-obese animals.

We have recently reported that central leptin infusion increases the hepatic response to a rise in brain insulin levels \[[@CR6]\]. Central leptin actions affect hepatic metabolism \[[@CR7], [@CR8]\]; however, its actions after a rise in peripheral glucose or insulin remain only partially characterized. Thus, we hypothesized that the improvement in glycemia after oral glucose or peripheral insulin administration in chronic leptin-infused non-obese rats could be explained by changes in glucose metabolism due to leptin-related changes in hepatic insulin sensitivity.

Methods {#Sec3}
=======

Animals {#Sec4}
-------

Thirty-six adult male Wistar rats (250 ± 10 g) were caged with a 12-h light/dark cycle and given standard chow and water *ad libitum*. After an overnight fast, rats were anesthetized and positioned in a stereotaxic apparatus. A cannula attached to an osmotic minipump (Alzet, Durect Corporation, Cupertino, CA) containing saline (controls, C) or leptin (Preprotech, Rocky Hill, NJ, USA; 12 μg/day) was implanted and maintained during 14 days (L), as reported \[[@CR6]\]. To discriminate the inhibitory effect of leptin on food intake, a pair-fed group (PF) was included. On the last day, twelve rats were fasted for 12 h and then sacrificed, obtaining trunk blood for the determination of glucose, leptin and insulin levels. The liver was weighed and processed for measurement of activation of insulin signaling targets, protein levels of glucose transporter (GLUT)2 and −4 and phosphoenolpyruvate carboxykinase (PEPCK). The weight of the gastrocnemius and subcutaneous and epididymal fat pads was also recorded.

Twelve rats were fasted for 12 h, followed by an oral glucose tolerance test (OGTT) (n = 4 per group). A bolus of glucose (2 g/kg body weight) was administered orally \[[@CR9]\]. Glycemia was determined (Accu-Check Sensor) in blood samples extracted from the tail vein before glucose administration and at 15, 30, 60 and 120 min, as well as insulin levels. The liver was processed after OGTT for measurement of free glucose and glycogen concentrations.

Insulin sensitivity was assessed after fasting by performing an intraperitoneal insulin tolerance test (IPITT) \[[@CR10]\] in the remaining twelve rats. After the injection of 1 U/kg of insulin, blood samples were drawn at 30, 60, 90 and 120 min for glucose measurements. The liver was extracted for determination of glucose and glycogen. This study was approved by the Ethics Committee of the Universidad de Alcalá de Henares.

ELISAs {#Sec5}
------

Serum leptin and insulin levels were measured using ELISA kits from Millipore Corporate Headquarters (Billerica, MA, USA). The intra- and inter-assay variations were lower than 10 %.

Western blotting {#Sec6}
----------------

Western blots were performed using antibodies against GLUT2, the beta chain of the insulin receptor (IRβ) and PEPCK from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and anti-GLUT4 from Millipore (Temecula, CA, USA). The proteins were detected by chemiluminiscence using an ECL system. Quantification of the bands was carried-out by densitometry using a Kodak Gel Logic 1500 Image Analysis system and Molecular Imaging software 4.0 (Rochester, NY, USA). Proteins were normalized with β-actin (Thermo Scientific, Fremont, CA, USA).

Multiplexed bead immunoassay {#Sec7}
----------------------------

Phosphorylated and total protein levels of IR substrate 1 (IRS1), Akt and phosphatase and tensin homolog on chromosome 10 (PTEN) were determined by a multiplexed bead immunoassay (Millipore). A minimum of 50 beads per parameter were analyzed in the Bio-Plex suspension array system 200 (Bio-Rad). Raw data (median fluorescence intensity, MFI) were analyzed with the Bio-Plex Manager Software 4.1 (Bio-Rad Laboratories).

Measurement of hepatic glucose and glycogen {#Sec8}
-------------------------------------------

Glucose was measured by an enzymatic method from Sigma-Aldrich (GAGO-20), in homogenized samples \[[@CR11]\]. For quantification of glycogen, liver samples were processed as previously reported \[[@CR6]\] and the resulting glucose concentrations determined by the same method.

Statistical analysis {#Sec9}
--------------------

Data are expressed as mean ± SEM. Statistical analysis was carried out by one-way ANOVA or repeated measures for OGTT or IPITT followed by a Bonferroni's test. Values were considered significantly different when the *P* value was less than 0.05. Analyses were conducted with Prisma software 4.00 (GraphPad, San Diego, CA, USA).

Results {#Sec10}
=======

General characteristics of the experimental groups {#Sec11}
--------------------------------------------------

Average daily food intake was reduced in PF and L and body weight gain was lower in these groups, with a more pronounced reduction in L (Table [1](#Tab1){ref-type="table"}). Basal values of serum glucose, leptin and insulin levels, as well as the weight of the liver, gastrocnemius and adipose tissue are given in Table [1](#Tab1){ref-type="table"}.Table 1General characteristics of the experimental groups.ParameterGroupControlPair-fedLeptinDaily food intake (g)10.11 ± 0.646.75 ± 0.40\*6.67 ± 0.39\*Δ body weight (g)41.82 ± 3.9722.50 ± 3.07\*\*3.12 ± 0.18\*\*^\#\#^Glucose (mg/dl)79.54 ± 4.6276.70 ± 2.0383.78 ± 3.20Leptin (ng/ml)4.08 ± 1.462.93 ± 0.3810.62 ± 2.93\*\*^\#\#^Insulin (ng/ml)0.80 ± 0.130.76 ± 0.090.83 ± 0.32Liver (g)9.71 ± 0.4910.12 ± 0.889.05 ± 1.04Gastrocnemius (g)0.96 ± 0.170.80 ± 0.121.19 ± 0.20^\#^Adipose tissue (g)8.07 ± 0.305.92 ± 0.71\*\*3.62 ± 0.18\*\*^\#\#^Values represent mean ± SEM of 4 rats per group. Weight of adipose tissue is the sum of subcutaneous and epididymal fat pads. \*p\<0.05, \*\*p\<0.01 vs. control group; ^\#^p\<0.05, ^\#\#^p\<0.01 vs. pair-fed group.

Leptin improves glycemia after glucose or insulin administration {#Sec12}
----------------------------------------------------------------

We found no differences in basal glycemia or insulin levels. A drop in glycemia was observed throughout the IPITT in all groups, being more pronounced in L at 60 and 90 min (Fig. [1a](#Fig1){ref-type="fig"}). Administration of glucose triggered a substantial increase in glycemia (Fig. [1b](#Fig1){ref-type="fig"}) and serum insulin levels (Fig. [1c](#Fig1){ref-type="fig"}) in all groups, with this increase being lower in PF and L with respect to C and in L compared to PF.Fig. 1Serum parameters during OGTT or IPITT and hepatic glucose and glycogen levels after these tests. **a**. Serum glucose levels before (0 min) and during (30, 60, 90 and 120 min) an intraperitoneal (IP) insulin tolerance test (IPITT). C + I, control rats that received an IP insulin bolus; PF + I, pair-fed rats that received an IP insulin bolus; L + I, rats treated with chronic icv leptin infusion that received an IP insulin bolus. **b**. Serum glucose levels before (0 min) and during (15, 30, 60 and 120 min) an oral glucose tolerance test (OGTT). C + G, control rats that received oral glucose; PF + G, pair-fed rats that received oral glucose; L + G, rats treated with chronic icv leptin infusion that received oral glucose. **c**. Serum insulin levels before and during an OGTT. **d**. Hepatic glucose levels after an IPITT. **e**. Hepatic glucose levels after an OGTT. **f**. Hepatic glycogen concentrations after an IPITT. **g**. Hepatic glycogen concentrations after an OGTT. \**p* \< 0.05 vs. C, ^\#^ *p* \< 0.05 vs PF, &*p* \< 0.05 vs. previous time-point in Fig. 1a-c or \**p* \< 0.05, \*\**p* \< 0.01 vs. C or PF in Fig. 1d-g

The effect of glucose or insulin overload on hepatic glucose and glycogen levels is potentiated by leptin {#Sec13}
---------------------------------------------------------------------------------------------------------

Hepatic glucose content was higher in L after IPITT (Fig. [1d](#Fig1){ref-type="fig"}) and lower in PF compared to both C and L rats and higher in L compared to C and PF rats after OGTT (Fig. [1e](#Fig1){ref-type="fig"}). Glycogen levels were higher in L after IPITT (Fig. [1f](#Fig1){ref-type="fig"}) and lower in PF compared to both Cand L rats and higher in L compared to C and PF rats after OGTT (Fig. [1g](#Fig1){ref-type="fig"}).

Hepatic insulin signaling is activated by leptin infusion {#Sec14}
---------------------------------------------------------

Hepatic GLUT2 protein levels were higher in L compared to both C and PF rats (Fig. [2a](#Fig2){ref-type="fig"}), whereas GLUT4 levels were unchanged (Fig. [2b](#Fig2){ref-type="fig"}). PEPCK protein levels were lower in L compared to the other two groups (Fig. [2c](#Fig2){ref-type="fig"}). Hepatic levels of IRβ were not modified (Fig. [2d](#Fig2){ref-type="fig"}). The phosphorylation of IRS1 was higher in L compared to C and PF rats (Fig. [2e](#Fig2){ref-type="fig"}). Phosphorylation of Akt on the Thr308 residue was increased in L with respect to C (Fig. [2f](#Fig2){ref-type="fig"}) and on Ser473 phosphorylation was increased in L compared to C and PF rats (Fig. [2g](#Fig2){ref-type="fig"}). Finally, PTEN phosphorylation was reduced in PF and L (Fig. [2h](#Fig2){ref-type="fig"}).Fig. 2Leptin infusion modifies insulin signaling and parameters related to glucose metabolism in the liver. **a**. Relative glucose transporter (GLUT)2 protein levels. C, control rats; PF, pair-fed rats and L, rats treated with chronic icv leptin infusion. **b**. Relative GLUT4 protein levels. **c**. Relative phosphoenolpyruvate carboxykinase (PEPCK) protein levels. **d**. Relative insulin receptor beta chain (IRβ) protein levels. **e**. Relative phosphorylated (p) insulin receptor substrate (IRS)1 protein levels. **f**. Relative pAkt on threonine 308 (pThr308Akt) protein levels. **g**. Relative pAkt on serine 473 (pSer473Akt) protein levels. **h**. Relative p-phosphatase and tensin homolog on chromosome 10 (PTEN) on serine 380 (pSer380PTEN) protein levels. DU, densitometry units; MFI, median fluorescent intensity; NS, non-significant; \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001

Discussion {#Sec15}
==========

The goal of this study was to examine the effect of central leptin infusion on glycemia after a peripheral increase in glucose or insulin and the possible relationship with changes in glucose uptake and its metabolism in the liver. We found that leptin-treated rats had higher hepatic glucose and glycogen concentrations, probably due to higher levels of GLUT2 \[[@CR12]\], thus regulating glycemia. Several differences between pair-fed and leptin-treated rats were observed, in particular, higher leptin concentrations in the leptin- infused group. In fact, leptin infusion causes hyperleptinemia \[[@CR13]\] as intracerebroventricular leptin goes to the periphery, as previously reported \[[@CR14]\]. In addition, the gastrocnemius of these rats weighs more than in the pair-fed group, as previously reported \[[@CR15]\], probably related to the leptin-induced increase in carbohydrate disposal \[[@CR16]\]. Likewise, the reduction in fat pads is most likely due to leptin's suppression of glucose utilization \[[@CR17]\].

Consistent with these findings, central leptin administration modifies glucose fluxes and production \[[@CR18], [@CR19]\] and these changes are partially mediated by increasing hepatic insulin sensitivity, as we report here. In fact, exogenous leptin has been shown to exert positive effects on peripheral insulin signaling that involve leptin-insulin cross-talk \[[@CR1]\]. Indeed, an increase in central leptin is reported to reverse hepatic insulin resistance \[[@CR7]\] and to correct peripheral glucose usage \[[@CR20]\]. The insulin and leptin signaling pathways share several targets, such as Janus kinase-2, IRSs and Akt \[[@CR21]\], and we have reported that interaction of these pathways potentiates insulin signaling \[[@CR6]\]. While muscle most likely participates in the regulation of serum glucose levels, as leptin increases insulin sensitivity in this tissue \[[@CR22]\], our results clearly indicate a key role of the liver in leptin's effects on serum glucose improvement.

Tolerance tests give more accurate information than homeostasis model assessment of insulin resistance to determine insulin sensitivity \[[@CR23], [@CR24]\]. Here, tolerance tests reveal that the higher concentrations of glucose and glycogen in the liver of leptin-infused rats may be related with its increased insulin sensitivity. These changes seem to be due to the higher degree of phosphorylation on both the Thr308 and Ser473 residues of Akt, which is necessary to achieve full activation of the insulin signaling cascade \[[@CR25]\].

In conclusion, our results suggest that improvement in glycemia after peripheral glucose or insulin administration in central leptin-infused rats is due, at least in part, to the previous activation of hepatic insulin signaling that may increase glucose uptake and glycogen storage, thus contributing to lower serum glucose levels.
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